TY - JOUR T1 - B type natriuretic peptide testing was more cost effective than conventional diagnosis in patients with acute dyspnoea JF - Evidence Based Medicine JO - Evid Based Med SP - 28 LP - 28 DO - 10.1136/ebm.12.1.28 VL - 12 IS - 1 A2 - , Y1 - 2007/02/01 UR - http://ebm.bmj.com/content/12/1/28.abstract N2 - Mueller C, Laule-Kilian K, Schindler C, et al. Cost-effectiveness of B-type natriuretic peptide testing in patients with acute dyspnea. Arch Intern Med 2006;166:1081–7.OpenUrlCrossRefPubMedWeb of Science 
 
 Q In patients who presented to the emergency department (ED) with acute dyspnoea, is a diagnostic strategy based on rapid measurement of B type natriuretic peptide (BNP) concentrations more cost effective than conventional diagnosis? Clinical impact ratings Respirology ★★★★★★☆ Internal medicine ★★★★★★☆ Emergency medicine ★★★★★☆☆ Cardiology ★★★★★☆☆ Design: cost effectiveness analysis of a randomised {allocation concealed*}†, blinded (outcome assessors*), controlled trial (B Type Natriuretic Peptide for Acute Shortness of Breath Evaluation [BASEL] study) with follow up of 180 days. Setting: ED in a university hospital in Basel, Switzerland. Patients: 452 patients (mean age 71 y, 58% men) who presented to the ED with acute dyspnoea. Exclusion criteria included trauma, severe renal disease, and cardiogenic shock. Intervention: diagnostic strategy with rapid measurement of BNP concentrations (n = 225) or conventional diagnostic strategy (n = 227). Outcomes: included all cause … ER -